Semaglutide Dosage and Usage Guidelines

Dosing Recommendations

For patients with type 2 diabetes or obesity, the American College of Cardiology recommends initiating subcutaneous semaglutide at 0.25 mg once weekly for 4 weeks, then increasing to 0.5 mg once weekly, with potential further increases to 1.0 mg weekly for diabetes (or 2.4 mg weekly for weight management) based on glycemic control and weight loss goals 1, 2
The initial dose for subcutaneous semaglutide is 0.25 mg once weekly at any time of day for 4 weeks, according to the Mayo Clinic Proceedings 1, 2
The maintenance dose for subcutaneous semaglutide is 0.5 mg once weekly after 4 weeks, as recommended by the Mayo Clinic Proceedings 1, 2
No dosage adjustments are required for patients with renal impairment, as stated by the Mayo Clinic Proceedings 1, 2
For patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, the initial dose is 0.25 mg once weekly, following the same titration schedule as for diabetes, according to the Mayo Clinic Proceedings and Diabetes Care 1, 2, 3
The weight management dose is 2.4 mg once weekly, as recommended by the Mayo Clinic Proceedings and Diabetes Care 1, 2, 3

Semaglutide provides cardiovascular benefits in patients with established cardiovascular disease, including reduced risk of cardiovascular mortality, MI, or stroke, as reported by Diabetes Care and the European Heart Journal 4, 5
The European Heart Journal recommends considering semaglutide in overweight or obese patients with chronic coronary syndrome without diabetes to reduce cardiovascular mortality, MI, or stroke 5, 6

For patients with type 2 diabetes and diabetic kidney disease, semaglutide is recommended with no dosage adjustments required, according to the Mayo Clinic Proceedings 1, 2, 7
Semaglutide has shown benefit in resolution of steatohepatitis for patients with non-alcoholic steatohepatitis, as reported by Gastroenterology 8

Weight regain occurs after discontinuation of semaglutide, suggesting long-term use is necessary for sustained benefit, as reported by JAMA 9
Continuous monitoring is recommended with clinical assessment at least monthly for the first 3 months and at least quarterly thereafter, according to Diabetes Care 3
Early response to semaglutide (typically >5% weight loss after 3 months) predicts long-term outcomes, as reported by Diabetes Care 3